Search

Frank J Schoenen

from Lawrence, KS
Age ~66
Get Report
Also known as:
Frank John Schoenen, Joni F Schoenen, Frank J Frank
Phone and address:
2328 Manchester Rd, Lawrence, KS 66049
(785) 856-3230
Related to:
Michael Madden, 61James A Fisher, 71Jasmin M Fisher, 39Robin M Fisher, 71Rosemary H SchoenenJoni F Schoenen, 62Kelly M Madden, 34Justin Fisher, 56Ella C Schoenen, 28Justin N Fisher, 37
Connected to:
Aaron M Schoenfeld, 34Alex Schoenfeld, 109Alexandra E Schoenfeld, 39Alyshia R Schoenfeld, 34Andrea E Schoenfelder, 56Andrew M Schoene, 42Anne M Schoenecker, 42Audrey E Schoener, 57Barbara E Schoenenberger, 63Bill Schoenfeld, 59

Frank Schoenen Phones & Addresses

  • 2328 Manchester Rd, Lawrence, KS 66049 (785) 856-3230
  • 915 Summerfield Ct, Laurence, KS 66049 (785) 856-3230
  • Kansas City, MO
  • 615 Lemontree Ln, Hillsborough, NC 27278 (919) 245-0131
  • Efland, NC
  • 3 Brandon Rd, Chapel Hill, NC 27514
  • Somerville, MA
  • 615 Lemontree Ln, Hillsborough, NC 27278 (919) 308-2457

Work

Position: Executive, Administrative, and Managerial Occupations

Education

Degree: High school graduate or higher

Publications

Us Patents

Compositions And Methods For Establishing And Maintaining Stem Cells In An Undifferentiated State

View page
US Patent:
8193235, Jun 5, 2012
Filed:
Jun 11, 2010
Appl. No.:
12/813688
Inventors:
Soumen Paul - Overland Park KS, US
Debasree Dutta - Kansas City KS, US
Soma Ray - Overland Park KS, US
Jeffrey Aube - Lawrence KS, US
Frank John Schoenen - Lawrence KS, US
Assignee:
University of Kansas - Kansas City KS
International Classification:
A61K 31/164
C07D 233/64
US Classification:
514408, 548400
Abstract:
The present invention embraces compositions and methods for establishing and maintaining stem cells and inhibiting stem cell differentiation using a selective Protein Kinase C (PKC) inhibitor.

Brca1-Based Breast Or Ovarian Cancer Treatment Agents And Methods Of Use

View page
US Patent:
8362072, Jan 29, 2013
Filed:
Jun 18, 2012
Appl. No.:
13/525831
Inventors:
Roy A. Jensen - Gardner KS, US
Frank J. Schoenen - Lawrence KS, US
Jeffrey Aube - Lawrence KS, US
Gerald H. Lushington - Lawrence KS, US
Assignee:
University of Kansas - Lawrence KS
International Classification:
A61K 31/34
US Classification:
514468, 514461, 514449, 514183, 549460, 549458, 549456, 549429, 549200
Abstract:
A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof; and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.

Compounds And Methods Of Use Thereof

View page
US Patent:
20080269204, Oct 30, 2008
Filed:
Oct 27, 2005
Appl. No.:
11/718284
Inventors:
Tatyana Dyakonov - Durham NC, US
Michael L. Jones - Chapel Hill NC, US
Christopher J. Markworth - Durham NC, US
Jessymol Mathew - Raleigh NC, US
Frank J. Schoenen - Lawrence KS, US
David S. Van Vliet - Chapel Hill NC, US
David Middlemiss - Bishop's Stortford, GB
International Classification:
C07D 279/16
A61K 31/5415
C07D 265/36
A61P 1/00
A61P 17/06
A61P 11/00
A61P 3/10
A61P 9/12
A61P 15/10
A61P 35/00
A61P 25/28
A61P 11/06
A61P 19/02
A61P 29/00
A61K 31/536
US Classification:
5142242, 544 52, 544105, 5142305
Abstract:
Benzolactam boronic acid compounds and pharmaceutical formulations are described along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof.

Compounds And Methods Of Use Thereof

View page
US Patent:
20080319044, Dec 25, 2008
Filed:
Oct 27, 2005
Appl. No.:
11/718286
Inventors:
John R. Didsbury - Raleigh NC, US
Tatyana A. Dyakonov - Durham NC, US
Simon N. Haydar - Newton PA, US
Michael L. Jones - Chapel Hill NC, US
Francine F. Li - Chester Springs PA, US
Christopher J. Markworth - Durham NC, US
Jessymol Mathew - Raleigh NC, US
Frank J. Schoenen - Lawrence KS, US
Jan J. Scicinski - Sunnyvale CA, US
David Middlemiss - Bishop's Stortford, GB
Assignee:
NUADA, LLC - Durham NC
International Classification:
A61K 31/404
C07D 209/04
A61P 1/00
A61P 19/02
A61P 17/06
A61P 25/28
A61P 9/00
A61P 3/10
A61P 35/00
A61P 9/12
A61P 15/10
US Classification:
514415, 548491
Abstract:
Indole boronic acid compounds, and analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof.

Compounds And Methods Of Use Thereof

View page
US Patent:
20090005344, Jan 1, 2009
Filed:
Oct 27, 2005
Appl. No.:
11/718277
Inventors:
James F. Burns - Raleigh NC, US
Leonardo A. Cabana - Cary NC, US
Glenn C. Collupy - Durham NC, US
John R. Didsbury - Raleigh NC, US
Tatyana A. Dyakonov - Durham NC, US
Simon N. Haydar - Newton PA, US
Michael L. Jones - Chapel Hill NC, US
Francine F. Li - Chester Springs PA, US
Christopher J. Markworth - Durham NC, US
Jessymol Mathew - Raleigh NC, US
Frank J. Schoenen - Lawrence KS, US
David S. Van Vliet - Chapel Hill NC, US
David Middlemiss - Bishop's Stortford, GB
Assignee:
NKUADA, LLC - Durham NC
International Classification:
A61K 31/4184
A61K 31/381
A61P 43/00
A61P 29/00
A61P 19/02
A61P 17/06
A61P 19/08
A61P 11/06
US Classification:
514 64, 5483097, 514394, 5483101, 548181, 514365, 548110, 568 6, 5483044, 546 13
Abstract:
Imidazole and benzimidazole boronic acid compounds, analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof.

Brca1-Based Breast Or Ovarian Cancer Prevention Agents And Methods Of Use

View page
US Patent:
20090170842, Jul 2, 2009
Filed:
Nov 13, 2008
Appl. No.:
12/270252
Inventors:
Roy A. Jensen - Gardner KS, US
Frank J. Schoenen - Lawrence KS, US
Jeffrey Aube - Lawrence KS, US
Gerald H. Lushington - Lawrence KS, US
Assignee:
University of Kansas - Lawrence KS
International Classification:
A61K 31/5375
A61K 31/423
A61K 31/426
A61K 31/4245
A61K 31/505
A61K 31/381
A61K 31/164
A61K 31/41
A61K 31/4709
A61K 31/343
A61K 31/415
A61K 31/34
A61K 31/13
A61K 31/44
A61K 31/4035
C07D 235/04
A61K 31/4184
C12N 5/00
A61P 35/00
US Classification:
5142312, 514375, 514616, 514370, 514364, 514274, 514438, 514617, 514395, 514381, 514357, 514314, 514468, 514404, 514350, 514471, 514638, 514352, 514416, 5483047, 514394, 435325
Abstract:
A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof, and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1.

Methods And Compositions For Inhibition Of The Transitional Endoplasmic Reticulum Atpase

View page
US Patent:
20110288082, Nov 24, 2011
Filed:
May 6, 2011
Appl. No.:
13/103003
Inventors:
Raymond J. Deshaies - Claremont CA, US
Tsui-Fen Chou - Pasadena CA, US
Frank J. Schoenen - Lawrence KS, US
Kelin Li - Lawrence KS, US
Kevin J. Frankowski - Lawrence KS, US
Jeffrey Aube - Lawrence KS, US
Samuel W. Gerritz - Guilford CT, US
Han-Jie Zhou - Foster City CA, US
International Classification:
A61K 31/538
A61K 31/53
A61K 31/4184
C40B 30/08
C12Q 1/34
C07D 239/95
C07D 413/04
C07D 403/04
C07D 495/04
C07D 401/04
C07D 417/04
C07D 409/12
C07D 417/12
C07D 413/14
C07D 401/14
A61P 43/00
A61K 31/517
US Classification:
5142305, 5142664, 514249, 5142662, 51426623, 51426621, 514245, 514394, 506 11, 435 18, 544291, 544105, 544284, 544 73
Abstract:
Compounds of Formulas I-XLIII are identified as direct inhibitors of p97 ATPase or of the degradation of a p97-dependent ubiquitin-proteasome system (UPS) substrate. Methods and compositions are disclosed for inhibiting p97 ATPase and the degradation of a p97-dependent UPS substrate, and for identifying inhibitors thereof

Compositions And Methods For Establishing And Maintaining Stem Cells In An Undiffferentiated State

View page
US Patent:
20120270313, Oct 25, 2012
Filed:
May 24, 2012
Appl. No.:
13/479878
Inventors:
Soumen Paul - Overland Park KS, US
Debasree Dutta - Kansas City KS, US
Soma Ray - Overland Park KS, US
Jeffrey Aube - Lawrence KS, US
Frank John Schoenen - Lawrence KS, US
Assignee:
University of Kansas - Lawrence KS
International Classification:
C12N 5/0735
C12N 5/074
C12N 5/095
C12N 5/07
US Classification:
435354, 435377, 435353, 435366
Abstract:
The present invention embraces compositions and methods for establishing and maintaining stem cells and inhibiting stem cell differentiation using a selective Protein Kinase C (PKC) inhibitor.
Control profile
Frank J Schoenen from Lawrence, KS, age ~66 Get Report